Abstract
Fibroblast growth factor 23 (FGF-23), primarily produced by osteocytes, is a phosphate-regulating hormone. The levels of FGF-23 increase along with the decline in kidney function. This occurs as a physiologic response to maintain normal serum phosphate levels and help maintain the average phosphate balance. Dysregulation in iron balance and inflammation occurred in chronic kidney disease, including patients with hemodialysis. This study aimed to determine the difference in serum calcium phosphate levels and iron status between regular hemodialysis patients with high and lower FGF-23 serum levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
